ARDX Ardelyx Inc
Price (delayed)
$5.6
Market cap
$1.32B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.28
Enterprise value
$1.38B
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate
Highlights
The company's revenue has surged by 153% YoY and by 32% QoQ
The company's gross profit has surged by 144% YoY and by 33% QoQ
The company's quick ratio has surged by 61% YoY but it fell by 12% QoQ
Ardelyx's equity has increased by 19% YoY but it has decreased by 2.6% QoQ
The net income has decreased by 16% YoY
The company's gross margin fell by 3.6% YoY
Key stats
What are the main financial stats of ARDX
Market
Valuations
Earnings
Shares outstanding
235.43M
Market cap
$1.32B
Enterprise value
$1.38B
Price to earnings (P/E)
N/A
Price to book (P/B)
8.91
Price to sales (P/S)
6.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.58
Revenue
$210M
EBIT
-$55.9M
EBITDA
-$50.48M
Free cash flow
-$85.82M
Per share
Balance sheet
Liquidity
EPS
-$0.28
Free cash flow per share
-$0.37
Book value per share
$0.63
Revenue per share
$0.9
TBVPS
$1.46
Total assets
$343.49M
Total liabilities
$196.5M
Debt
$104.9M
Equity
$146.99M
Working capital
$200.58M
Debt to equity
0.71
Current ratio
4.21
Quick ratio
3.57
Net debt/EBITDA
-1.25
Margins
Efficiency
Dividend
EBITDA margin
-24%
Gross margin
86%
Net margin
-31%
Operating margin
-28%
Return on assets
-20.5%
Return on equity
-39.7%
Return on invested capital
-18.2%
Return on capital employed
-19.9%
Return on sales
-26.6%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARDX stock price
How has the Ardelyx stock price performed over time
Intraday
-2.95%
1 week
-9.39%
1 month
-7.89%
1 year
18.39%
YTD
-9.68%
QTD
-24.43%
Financial performance
How have Ardelyx's revenue and profit performed over time
Revenue
$210M
Gross profit
$180.67M
Operating income
-$58.9M
Net income
-$65.15M
Gross margin
86%
Net margin
-31%
The company's revenue has surged by 153% YoY and by 32% QoQ
The company's gross profit has surged by 144% YoY and by 33% QoQ
ARDX's operating margin has surged by 56% year-on-year and by 28% since the previous quarter
Ardelyx's net margin has surged by 54% YoY and by 25% QoQ
Growth
What is Ardelyx's growth rate over time
Valuation
What is Ardelyx stock price valuation
P/E
N/A
P/B
8.91
P/S
6.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.58
The EPS has declined by 17% year-on-year but it has increased by 3.4% since the previous quarter
ARDX's P/B is 78% above its 5-year quarterly average of 5.0 but 2.1% below its last 4 quarters average of 9.1
Ardelyx's equity has increased by 19% YoY but it has decreased by 2.6% QoQ
The company's revenue has surged by 153% YoY and by 32% QoQ
The price to sales (P/S) is 83% lower than the 5-year quarterly average of 37.6 and 32% lower than the last 4 quarters average of 9.2
Efficiency
How efficient is Ardelyx business performance
The company's return on invested capital has surged by 66% YoY and by 20% QoQ
The return on sales has surged by 58% year-on-year and by 28% since the previous quarter
Ardelyx's ROA has increased by 30% YoY and by 11% from the previous quarter
Ardelyx's ROE has increased by 27% YoY and by 4.8% from the previous quarter
Dividends
What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARDX.
Financial health
How did Ardelyx financials performed over time
ARDX's total assets is 75% greater than its total liabilities
ARDX's total liabilities has surged by 123% year-on-year and by 2.6% since the previous quarter
ARDX's total assets has surged by 63% year-on-year
Ardelyx's debt is 29% lower than its equity
Ardelyx's debt to equity has surged by 154% YoY
Ardelyx's equity has increased by 19% YoY but it has decreased by 2.6% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.